Real‐World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First‐Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort Study
- DOI
- 10.1002/jha2.70432
- Published
- 2026-11-05
- Container
- eJHaem
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1002/jha2.70432,
title = {Real‐World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First‐Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort Study},
author = {John M. Burke and Ira Zackon and Yunfei Wang and Kathleen M. Aguilar and John Murphy and Brittani Wayne and Jennifer Prescott and Siyang Leng and Inkyu Kim and Diana Chirovsky and Enrico de Nigris},
year = {2026},
journal = {eJHaem},
doi = {10.1002/jha2.70432},
url = {https://doi.org/10.1002/jha2.70432}
}RIS
TY - JOUR TI - Real‐World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First‐Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort Study AU - John M. Burke AU - Ira Zackon AU - Yunfei Wang AU - Kathleen M. Aguilar AU - John Murphy AU - Brittani Wayne AU - Jennifer Prescott AU - Siyang Leng AU - Inkyu Kim AU - Diana Chirovsky AU - Enrico de Nigris PY - 2026 JO - eJHaem DO - 10.1002/jha2.70432 UR - https://doi.org/10.1002/jha2.70432 ER -
APA
Burke, J. M., Zackon, I., Wang, Y., Aguilar, K. M., Murphy, J., Wayne, B., Prescott, J., Leng, S., Kim, I., Chirovsky, D., & Nigris, E. D. (2026). Real‐World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First‐Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort Study. eJHaem. https://doi.org/10.1002/jha2.70432
Source records
- crossref · retrieved 2026-11-07T20:29:39.450Z